Many treatments for the epilepsies and affective disorder share the properties of seizure suppression and mood stabilization. Moreover, affective disorders and the epilepsies appear to share partially similar pathogenic mechanisms. A component of the shared predisposition appears to arise from noradrenergic and serotonergic deficits. Increasing evidence supports the hypothesis that noradrenergic and/or serotonergic elevation is a mechanism of therapeutic benefit shared by most antidepressants and many antiepileptic medications. Medication induced alterations in GABAergic, glutamatergic, and CRH (corticotropin releasing hormone) containing neurons may also contribute to the shared therapeutic properties of antidepressant and antiepileptic medications.
DaileyJWNaritokuDK. Antidepressants and seizures: Clinical anecdotes overshadow neuroscience. Biochem Pharmacol1996;52:1323–1329.
2.
BallengerJC. The clinical use of carbamazepine in affective disorders. J Clin Psychiatry1988;49(suppl1): 13–21.
3.
DenicoffKDSmith-JacksonEEDisneyERAliSOLeverichGSPostRM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry1997;58(11): 470–478.
4.
DietrichDEKroppSEmrichHM. Oxcarbazepine in affective and schizoaffective disorders. Pharmacopsychiatry2001;34(6): 242–250.
5.
FerrierIN. Developments in mood stabilisers. Br Med Bull2001;57:179–192.
6.
PostRMUhdeTWBallengerJC. Efficacy of carbamazepine in affective disorders: Implications for underlying physiological and biochemical substrates. In: EmrichHMOkumaTMullerAA, (eds). Anticonvulsants in Affective Disorders. Amsterdam: Elsevier Science Publishers, B.V.; 1984: 93–115.
7.
PostRMKetterTAPazzagliaPJDenicoffKGeorgeMSCallahanA. Rational polypharmacy in the bipolar affective disorders. Epilepsy Res1996;11(suppl): 153–180.
8.
WaldenJHesslingerB.Value of old and new anticonvulsants in treatment of psychiatric diseases. Fortschr Neurol Psychiatr1995;63:320–335.
9.
MarangellLBRushAJGeorgeMSSackeimHAJohnsonCRHusainMM. Vagus nerve stimulation (VNS) for major depressive episodes: One year outcomes. Biol Psychiatry2002;51(4): 280–287.
10.
RushAJGeorgeMSSackeimHAMarangellLBHusainMMGillerC. Vagus nerve stimulation (VNS) for treatment-resistant depressions: A multicenter study. Biol Psychiatry2000;47(4): 276–286.
11.
SchachterSC. Vagus nerve stimulation: Where are we?Curr Opin Neurol2002;15(2): 201–206.
12.
GrunzeHWaldenJ.Relevance of new and newly rediscovered anticonvulsants for atypical forms of bipolar disorder. J Affect Disord2002;72(suppl): 21.
13.
TheodoreW.Transcranial magnetic stimulation in epilepsy. In: McLeanMJEngstromSHolcombRR, (eds). Magnetotherapy: Potential Therapeutic Benefits and Adverse Effects. Nashville, TN: TFG Press; 2003: 233–246.
14.
PostRMSpeerAM. Repetitive transcranial magnetic stimulation (rTMS) of the brain in the treatment of affective disorders. In: McLeanMJEngstromSHolcombRR, (eds). Magnetotherapy Potential Therapeutic Benefits and Adverse Effects. Nashville, TN: TFG Press; 2003: 209–232.
15.
ChwehAYSwinyardEAWolfHHKupferbergHJ. Correlations among minimal neurotoxicity, anticonvulsant activity, and displacing potencies in a3Hßflunitrazepam binding of benzodiazepines. Epilepsia1983;24:668–677.
16.
KrallRLPenryJKWhiteBGKupferbergHJSwinyardEA. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia1978;19: 409–428.
17.
KrallRLPenryJKKupferbergHJSwinyardEA. Antiepileptic drug development: I. History and a program for progress. Epilepsia1978;19: 393–408.
18.
KupferbergHJ. Antiepileptic drug development program: A cooperative effort of government and industry. Epilepsia1989;30(suppl1): S51–S56.
19.
MulzacDScottKR. Profile of anticonvulsant activity and minimal toxicity of methyl 4–[(p-chlorophenyl)amino]-6-methyl-2-oxo-cyclohex-3-en-1-oate and some prototype antiepileptic drugs in mice and rats. Epilepsia1993;34(6): 1141–1146.
20.
ScottKREdafioghoIORichardsonELFarrarVAMooreJATietzEL. Synthesis and anticonvulsant activity of enaminones. II. Further structure-activity correlations. J Med Chem1993;36(14): 1947–1955.
21.
JobePCPicchioniALChinL.Role of brain norepinephrine in audiogenic seizure in the rat. J Pharmacol Exp Ther1973;184:1–10.
22.
JobePCWoodsTWDaileyJW. Proconvulsant and anticonvulsant effects of tricyclic antidepressants in genetically epilepsy-prone rats. Epilepsy International Symposium 1983: 229. Abstract.
23.
DaileyJWJobePC. Anticonvulsant drugs and the genetically epilepsy-prone rat. Fed Proc1985;44:2640–2644.
24.
WoodsTWDaileyJWReigelCEJobePC. Anticonvulsant and proconvulsant effects of doxepin in the genetically epilepsy-prone rat (GEPR). Fed Proc1985;44:1107. Abstract.
25.
JobePCWoodsTWMcNultyMDaileyJW. Anticonvulsant and proconvulsant effects of tricyclic antidepressants. Fed Proc1984;43:569. Abstract.
26.
FrommGHWesselHBGlassJDAlvinJDVan HornG.Imipramine in absence and myoclonic-astatic seizures. Neurology1978;28(9 Pt 1): 953–957.
27.
FrommGHAmoresCYThiesW.Imipramine in epilepsy. Arch Neurol1972;27:198–204.
28.
OjemannLMFrielPNTrejoWJDudleyDL. Effect of doxepin on seizure frequency in depressed epileptic patients. Neurology1983;33:646–648.
29.
OjemannLMBaugh-BookmanCDudleyDL. Effect of psychotropic medications on seizure control in patients with epilepsy. Neurology1987;37(9): 1525–1527.
30.
LoscherWLehmannHTeschendorfHJTrautMGrossG.Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther1999;288(3): 984–992.
31.
HeningerGR. Antidepressants. In: GelderMGLopez-LborJJAndreasenNC, (eds). New Oxford Textbook of Psychiatry; 2000: 1293–1305.
32.
FavaleERubinoVMainardiPLunardiGAlbanoC.Anticonvulsant effect of fluoxetine in humans. Neurology1995;45:1926–1927.
33.
BrowningRAWoodAVMerrillMADaileyJWJobePC. Enhancement of the anticonvulsant effect of fluoxetine following blockade of 5-HT1A receptors. Eur J Pharmacol1997;336:1–6.
34.
DaileyJWYanQSMishraPKBurgerRLJobePC. Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats. J Pharmacol Exp Ther1992;260:533–540.
35.
YanQSJobePCDaileyJW. Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. Eur J Pharmacol1993;252(1): 105–112.
36.
YanQSJobePCCheongJHKoKHDaileyJW. Role of serotonin in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. Naunyn Schmiedebergs Arch Pharmacol1994;350:149–152.
37.
DaileyJWYanQSAdams-CurtisLERyuJRKoKHMishraPK. Neurochemical correlates of antiepileptic drugs in the genetically epilepsy-prone rat (GEPR). Life Sci1996;58(4): 259–266.
38.
YanQSJobePCDaileyJW. Further evidence of anticonvulsant role for 5-hydroxytryptamine in genetically epilepsy-prone rats. Br J Pharmacol1995;115:1314–1318.
39.
SneadOC. Basic mechanisms of generalized absence seizures. Ann Neurol1995;37(2): 146–157.
40.
JobePCDaileyJW. Genetically epilepsy-prone rats (GEPRs) in drug research. CNS Drug Rev2000;6(3): 241–260.
41.
CoffeyLLReithMEAChenNHJobePCMishraPK. Amygdala kindling of forebrain seizures and the occurrence of brainstem seizures in genetically epilepsy-prone rats. Epilepsia1996;37(2): 188–197.
42.
McNamaraJO. Kindling model of epilepsy. Adv Neurol1986;44:303–318.
43.
JobePCMishraPKDaileyJWKoKHReithMEA. Genetic predisposition to partial (focal) seizures and to generalized tonic/clonic seizures: Interactions between seizure circuitry of the forebrain and brainstem. In: BerkovicSFGentonPHirschEPicardF, (eds). Genetics of Focal Epilepsies. Avignon, France: John Libbey & Company, Ltd.; 1999: 251–260.
44.
JobePC. Are there specific anatomical and/or transmitter systems (cortical or subcortical) that should be targeted?Int Rev Neurobiol2002;49:221–252.
45.
BrowningRA. Effect of lesions on seizures in experimental animals. In: FrommGHFaingoldCLBrowningRABurnhamWM, (eds). Epilepsy and the Reticular Formation: The Role of the Reticular Core in Convulsive Seizures. New York: Alan R. Liss; 1987: 137–162.
46.
BrowningRA. The electroshock model, neuronal networks and antiepileptic drugs. In: FaingoldCLFrommGH, (eds). Drugs for Control of Epilepsy: Actions on Neuronal Networks Involved in Seizure Disorders. Boca Raton, Florida: CRC Press, Inc.; 1992: 195–211.
47.
BurnhamWM. Electrical stimulation studies: Generalized convulsions triggered from the brain-stem. In: FrommGHFaingoldCLBrowningRABurnhamWM, (eds). The Role of the Reticular Core in Convulsive Seizures. New York: Alan R. Liss; 1987: 25–38.
48.
BurnhamWMBrowningRA. The reticular core and generalized convulsions: A unified hypothesis. In: FrommGHFaingoldCLBrowningRABurnhamWM, (eds). Epilepsy and the Reticular Formation: The Role of the Reticular Core in Convulsive Seizures. New York: Alan R. Liss; 1987: 193–201.
49.
FrommGH. The brain-stem and seizures: Summary and synthesis. In: FrommGHFaingoldCLBrowningRABurnhamWM, (eds). Epilepsy and the Reticular Formation: The Role of the Reticular Core in Convulsive Seizures. New York: Alan R. Liss, Inc.; 1987: 203–218.
50.
BrowningRANelsonDK. Modification of electroshock and pentylenetetrazol seizure patterns in rats after precollicular transections. Exp Neurol1986;93:546–556.
51.
BrowningRA. Role of the brain-stem reticular formation in tonic-clonic seizures: Lesion and pharmacological studies. Fed Proc1985;44:2425–2431.
52.
MerrillMACloughRWJobePCBrowningRA. Role of the superior colliculus and the intercollicular nucleus in the brainstem seizure circuitry of the genetically epilepsy-prone rat. Epilepsia2003;44(3): 305–314.
53.
ChakravartyDNFaingoldCL. Differential roles in the neuronal network for audiogenic seizures are observed among the inferior colliculus subnuclei and the amygdala. Exp Neurol1999;157(1): 135–141.
54.
FaingoldCL. Neuronal networks in the genetically epilepsy-prone rat. Adv Neurol1999;79:311–321.
55.
FaingoldCL. Neuronal networks, epilepsy, and the action of antiepileptic drugs. In: FaingoldCLFrommGH, (eds). Drugs for Control of Epilepsy: Actions on Neuronal Networks Involved in Seizure Disorders. Boca Raton: CRC Press; 1992: 1–21.
56.
FaingoldCLRandallME. Neurons in the deep layers of superior colliculus play a critical role in the neuronal network for audiogenic seizures: Mechanisms for production of wild running behavior. Brain Res1999;815(2): 250–258.
57.
Beitner-JohnsonDGuitartXNestlerEJ. Dopaminergic brain reward regions of Lewis and Fischer rats display different levels of tyrosine hydroxylase and other morphine- and cocaine-regulated phosphoproteins. Brain Res1991;561(1): 147–150.
58.
BerridgeKC. Food reward: Brain substrates of wanting and liking. Neurosci Biobehav Rev1996;20(1): 1–25.
59.
BerridgeKCRobinsonTE. What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience?Brain Res Brain Res Rev1998;28(3): 309–369.
60.
DayanPBalleineBW. Reward, motivation, and reinforcement learning. Neuron2002;36(2): 285–298.
61.
de la Fuente-FernandezRPhillipsAGZamburliniMSossiVCalneDBRuthTJ. Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res2002;136(2): 359–363.
62.
KoobGF. Animal models of craving for ethanol. Addiction2000;95(suppl2):S73–S81.
63.
SalamoneJDCorreaM.Motivational views of reinforcement: Implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res2002;137(1–2): 3–25.
64.
SchultzW.Getting formal with dopamine and reward. Neuron2002;36(2): 241–263.
65.
WiseRA. Neurobiology of addiction. Curr Opin Neurobiol1996;6:243–251.
66.
WiseRA. Brain reward circuitry: Insights from unsensed incentives. Neuron2002;36(2): 229–240.
67.
Lingford-HughesANuttD.Neurobiology of addiction and implications for treatment. Br J Psychiatry2003;182:97–100.
68.
NaranjoCATremblayLKBustoUE. The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry2001;25(4): 781–823.
69.
BrodyALBarsomMWBotaRGSaxenaS.Prefrontal-subcortical and limbic circuit mediation of major depressive disorder. Semin Clin Neuropsychiatry2001;6(2): 102–112.
70.
DrevetsWCBogersWRaichleME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol2002;12(6): 527–544.
71.
DavidsonRJLewisDAAlloyLBAmaralDGBushGCohenJD. Neural and behavioral substrates of mood and mood regulation. Biol Psychiatry2002;52(6): 478–502.
72.
ByrumCEThompsonJEHeinzERKrishnanKRTienRD. Limbic circuits and neuropsychiatric disorders: Functional anatomy and neuroimaging findings. Neuroimaging Clin N Am1997;7(1): 79–99.
73.
JobePCMishraPKBrowningRAWangCAdams-CurtisLEKoKH. Noradrenergic abnormalities in the genetically epilepsy-prone rat. Brain Res Bull1994;35(5–6): 493–504.
74.
JobePCBrownRDDaileyJW. Effect of Ro 4–1284 on audiogenic seizure susceptibility and intensity in epilepsy-prone rats. Life Sci1981;28:2031–2038.
75.
ApplegateCDTecottLH. Global increases in seizure susceptibility in mice lacking 5-HT2C receptors: A behavioral analysis. Exp Neurol1998;154(2): 522–530.
76.
ShouseMNStabaRJKoPYSaquibSFFarberPR. Monoamines and seizures: Microdialysis findings in locus ceruleus and amygdala before and during amygdala kindling. Brain Res2001;892(1): 176–192.
77.
WadaYShiraishiJNakamuraMHasegawaH.Prolonged but not acute fluoxetine administration produces its inhibitory effect on hippocampal seizures in rats. Psychopharmacology (Berl)1995;118:305–309.
78.
ApplegateCDBurchfielJL. Microinjections of GABA agonists into the amygdala complex attenuates kindled seizure expression in the rat. Exp Neurol1988;102:185–189.
79.
AvoliM.GABA-mediated synchronous potentials and seizure generation. Epilepsia1996;37:1035–1042.
80.
FaingoldCLMarcinczykMJCasebeerDJRandallMEAmericSPBrowningRA. GABA in the inferior colliculus plays a critical role in control of audiogenic seizures. Brain Res1994;640:40–47.
81.
FaingoldCLGehlbachGTravisMACasparyDM. Inferior colliculus neuronal response abnormalities in genetically epilepsy-prone rats: Evidence for a deficit of inhibition. Life Sci1986;39:869–878.
82.
GaleK.GABA and epilepsy: Basic concepts from preclinical research. Epilepsia1992;33(suppl15): S3–12.
83.
GaleK.Progression and generalization of seizure discharge: Anatomical and neurochemical substrates. Epilepsia1988;29(suppl12): S15–S34.
84.
GaleK.Role of GABA in the genesis of chemoconvulsant seizures. Toxicol Lett1992;64(5): 417–428.
85.
DuringMJSpencerDD. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet1993;341:1607–1610.
86.
DuringMJRyderKMSpencerDD. Hippocampal GABA transporter function in temporal-lobe epilepsy [see comments], Nature1995;376:174–177.
87.
FaingoldCLNaritokuDKCopleyCARandallMERiazAAndersonCA. Glutamate in the inferior colliculus plays a critical role in audiogenic seizure initiation. Epilepsy Res1992;13:95–105.
88.
FlavinHJWieraszkoASeyfriedTN. Enhanced aspartate release from hippocampal slices of epileptic (El) mice. J Neurochem1991;56:1007–1011.
89.
MaresPChinoMKubovaHMathernPVelikyM.Convulsant action of systemically administered glutamate and bicuculline methiodide in immature rats. Epilepsy Res2000;42(2–3): 183–189.
90.
MeldrumBS. The role of glutamate in epilepsy and other CNS disorders. Neurology1994;44:14–23.
91.
PireddaSGaleK.A crucial epileptogenic site in the deep prepiriform cortex. Nature1985;317:623–625.
92.
WasterlainCGLiuHMazaratiAMBaldwinRAShirasakaYKatsumoriH. Self-sustaining status epilepticus: A condition maintained by potentiation of glutamate receptors and by plastic changes in substance P and other peptide neuromodulators. Epilepsia2000;41(suppl6): S134–S143.
93.
BaramTZSchultzL.Corticotropin-releasing hormone is a rapid and potent convulsant in the infant rat. Dev Brain Res1991;61(1): 97–101.
94.
BaramTZMitchellWGBrunsonKHadenE.Infantile spasms: Hypothesis-driven therapy and pilot human infant experiments using corticotropin-releasing hormone receptor antagonists. Dev Neurosci1999;21(3–5): 281–289.
95.
WeissSRPostRMGoldPWChrousosGSullivanTLWalkerD. CRF-induced seizures and behavior: Interaction with amygdala kindling. Brain Res1986;372(2): 345–351.
96.
JobePCDaileyJWWernickeJF. A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Crit Rev Neurobiol1999;13(4): 317–356.
97.
NeumeisterAPraschak-RiederNHebetaelmannBRaoMLGluckJKasperS.Effects of tryptophan depletion on drug-free patients with seasonal affective disorder during a stable response to bright light therapy. Arch Gen Psychiatry1997;54(2): 133–138.
98.
NeumeisterATurnerEHMatthewsJRPostolacheTTBarnettRLRauhM. Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Arch Gen Psychiatry1998;55(6): 524–530.
99.
NeumeisterAPraschak-RiederNHesselmannBVitouchORauhMBarockaA. Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. Am J Psychiatry1997;154(8): 1153–1155.
100.
LamRWTarnEMGrewalAYathamLN. Effects of alpha-methyl-para-tyrosine-induced catecholamine depletion in patients with seasonal affective disorder in summer remission. Neuropsychopharmacology2001;25(suppl5): S97–S101.
101.
BermanRMNarasimhanMMillerHLAnandACappielloAOrenDA. Transient depressive relapse induced by catecholamine depletion: Potential phenotypic vulnerability marker?Arch Gen Psychiatry1999;56(5): 395–403.
102.
BrostedtEMPedersenNL. Stressful life events and affective illness. Acta Psychiatr Scand2003;107(3): 208–215.
103.
SchousboeA.Role of astrocytes in the maintenance and modulation of glutamatergic and GABAergic neurotransmission. Neurochem Res2003;28(2): 347–352.
FaingoldCLAndersonBoersma CACasparyDM. Involvement of GABA in acoustically-evoked inhibition in inferior colliculus neurons. Hear Res1991;52:201–216.
106.
OlsenRWDe LoreyTMGordeyMKangMH. GABA receptor function and epilepsy. Adv Neurol1999;79:499–510.
107.
FaingoldCL. Role of GABA abnormalities in the inferior colliculus pathophysiology - audiogenic seizures. Hear Res2002;168(1–2): 223–237.
108.
BenesFMBerrettaS.GABAergic interneurons: Implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology2001;25(1): 1–27.
109.
BrunsonKLAvishai-ElinerSBaramTZ. ACTH treatment of infantile spasms: Mechanisms of its effects in modulation of neuronal excitability. Int Rev Neurobiol2002;49:185–197.
110.
HabibKEGoldPWChrousosGP. Neuroendocrinology of stress. Endocrinol Metab Clin North Am2001;30(3): 695–728.
111.
KawaharaHKawaharaYWesterinkBH. The role of afferents to the locus coeruleus in the handling stress-induced increase in the release of noradrenaline in the medial prefrontal cortex: A dual-probe microdialysis study in the rat brain. Eur J Pharmacol2000;387(3): 279–286.
112.
SchulzCKretzMLehnertH.Activation of noradrenergic neurons in the locus coeruleus by corticotropin-releasing hormone. Society for Neuroscience Abstracts 1993:19 Abstracts.
113.
ChaouloffF.Serotonin, stress and corticoids. J Psychopharmacol2000;14(2): 139–151.
114.
KirbyLGRiceKCValentinoRJ. Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology2000;22(2): 148–162.
MassatISoueryDDel FaveroJOrucLNoethenMMBlackwoodD. Excess of allele1 for alpha3 subunit GABA receptor gene (GABRA3) in bipolar patients: A multicentric association study. Mol Psychiatry2002;7(2): 201–207.
117.
HeckersSStoneDWalshJShickJKoulPBenesFM. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry2002;59(6): 521–529.
118.
CotterDLandauSBeasleyCStevensonRChanaGMacMillanL. The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol Psychiatry2002;51(5): 377–386.
119.
DuffyATureckiGGrofPCavazzoniPGrofEJooberR. Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium-responsive bipolar disorder. J Psychiatry Neurosci2000;25(4): 353–358.
120.
SquiresRFSaederupE.A review of evidence for GABAergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: More support for a continuum hypothesis of “functional” psychosis. Neurochem Res1991;16(10): 1099–1111.
121.
BjorkJMMoellerFGKramerGLKramMSurisARushAJ. Plasma GABA levels correlate with aggressiveness in relatives of patients with unipolar depressive disorder. Psychiatry Res2001;101(2): 131–136.
122.
ShiahISYathamLN. GABA function in mood disorders: An update and critical review. Life Sci1998;63(15): 1289–1303.
123.
KalenPStreckerRERosengrenEBjorklundA.Regulation of striatal serotonin release by the lateral habenula- dorsal raphe pathway in the rat as demonstrated by in vivo micro-dialysis: Role of excitatory amino acids and GABA. Brain Res1989;492:187–202.
124.
BonannoGRaiteriM.Release-regulating GABAA receptors are present on noradrenergic nerve terminals in selective areas of the rat brain. Synapse1987;1(3): 254–257.
125.
Aston-JonesGShipleyMTChouvetGEnnisMvan BockstaeleEPieriboneV. Afferent regulation of locus coeruleus neurons: Anatomy, physiology and pharmacology. Prog Brain Res1991;88:47–75.
126.
ShefnerSAOsmanovicSS. GABAA and GABAB receptors and the ionic mechanisms mediating their effects on locus coeruleus neurons. Prog Brain Res1991;88:187–195.
127.
KasckowJWBakerDGeraciotiTDJr. Corticotropin-releasing hormone in depression and post-traumatic stress disorder. Peptides2001;22(5): 845–851.
128.
GoldPWChrousosGP. Organization of the stress system and its dysregulation in melancholic and atypical depression: High vs low CRH/NE states. Mol Psychiatry2002;7(3): 254–275.
129.
NemeroffCB. New directions in the development of antidepressants: The interface of neurobiology and psychiatry. Hum Psychopharmacol2002;17(suppl1): S13–S16.
130.
AldaMTureckiGGrofPCavazzoniPDuffyAGrofE. Association and linkage studies of CRH and PENK genes in bipolar disorder: A collaborative IGSLI study. Am J Med Genet2000;96(2): 178–181.
131.
HatalskiCGGuirguisCBaramTZ. Corticotropin releasing factor mRNA expression in the hypothalamic paraventricular nucleus and the central nucleus of the amygdala is modulated by repeated acute stress in the immature rat. J Neuroendocrinol1998;10(9): 663–669.
132.
HandGAHewittCBFulkLJStockHSCarsonJADavisJM. Differential release of corticotropin-releasing hormone (CRH) in the amygdala during different types of stressors. Brain Res2002;949(1–2): 122–130.
133.
BelNArtigasF.Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse1993;15:243–245.
134.
ItohYOishiRNishiboriMSaekiK.In vivo measurement of noradrenaline and 3,4– dihydroxyphenylethyleneglycol in the rat hypothalamus by microdialysis: Effects of various drugs affecting noradrenaline metabolism, J Pharmacol Exp Ther1990;255:1090–1097.
135.
KreissDSLuckiI.Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther1995;274:866–876.
136.
MoretCBrileyM.Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain. Eur J Pharmacol1996;295:189–197.
137.
RamaiyaAJohnsonJHKarnesHT. Evaluation of the neuropharmacodynamics of paroxetine in vivo utilizing microdialysis. J Pharm Sci1997;86(12): 1497–1500.
138.
YanQSJobePCDaileyJW. Noradrenergic mechanisms for the anticonvulsant effects of desipramine and yohimbine in genetically epilepsy-prone rats: Studies with microdialysis. Brain Res1993;610:24–31.
139.
YanQSBurgerRJobePCDaileyJW. Anticonvulsant doses of fluoxetine increase dialyzable serotonin from the thalamus of genetically epilepsy-prone rats (GEPRs). FASEB J Abstract1990;4(3 part 1): 465. Abstract.
140.
JobePCPicchioniALChinL.Role of brain 5-hydroxytryptamine in audiogenic seizure in the rat. Life Sci1973;13:1–13.
141.
JobePC. Relationship of brain amine metabolism to audiogenic seizure in the rat. Diss Abs Int1970;31:5. Abstract.
142.
MishraPKKahleEHBettendorfAFDaileyJWJobePC. Anticonvulsant effects of intracerebroventricularly administered norepinephrine are potentiated in the presence of monoamine oxidase inhibition in severe seizure genetically epilepsy-prone rats (GEPR-9s). Life Sci1993;52:1435–1441.
143.
BaldessariniRJ. Drugs and the treatment of psychiatric disorders: Depression and anxiety disorders. In: HardmanJGLimbirdLE, (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 2001: 447–483.
144.
FinbergJPMPacakKKopinIJGoldsteinDS. Chronic inhibition of monoamine oxidase type-a increases noradrenaline release in rat frontal cortex. Naunyn Schmiedebergs Arch Pharmacol1993;347:500–505.
145.
BoyerPBrileyM.Milnacipran, a new specific serotonin and noradrenaline reuptake inhibitor. Drugs of Today1988;34:709–720.
146.
BrileyMProstJFMoretC.Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol1996;11(suppl4): 9–14.
147.
PalvimakiEPLaaksoAKuoppamakiMSyvalahtiEHietalaJ.Up-regulation of beta 1-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. Psychopharmacology1994;115:543–546.
148.
PageMEAbercrombieED. An analysis of the effects of acute and chronic fluoxetine on extracellular norepinephrine in the rat hippocampus during stress. Neuropsychopharmacology1997;16(6): 419–425.
149.
SeoDOShinCYLeeCJDaileyJWReithMEAJobePC. Effect of alterations in extracellular norepinephrine on adrenoceptors: A microdialysis study in freely moving rats. Eur J Pharmacol1999;365:39–46.
150.
SeoDOShinCYRyuJRCheongJHChoiCRDaileyJW. Effect of norepinephrine release on adrenoceptors in severe seizure genetically epilepsy-prone rats. Eur J Pharmacol2000;396(2–3): 53–58.
151.
BaldessariniRJ. Drugs and the treatment of psychiatric disorders: Depression and mania, In: HardmanJGLimbirdLEMolinoffPBRuddonRWGilmanAG, (eds). The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 1996: 431–459.
152.
MeijerJHGroosGA. Responsiveness of suprachiasmatic and ventral lateral geniculate neurons to serotonin and imipramine: A microiontophoretic study in normal and imipramine-treated rats. Brain Res Bull1988;20(1): 89–96.
153.
MenkesDBAghajanianGK. Alpha 1-Adrenoceptor-mediated responses in the lateral geniculate nucleus are enhanced by chronic antidepressant treatment. Eur J Pharmacol1981;74:27–35.
154.
MenkesDBAghajanianGKMcCallRB. Chronic antidepressant treatment enhances alpha-adrenergic and serotonergic responses in the facial nucleus. Life Sci1980;27:45–55.
BlierPde MontignyC.Effect of chronic tricyclic antidepressant treatment on the serotonergic autoreceptor: A microiontophoretic study in the rat. Arch Pharm1980;314:123–128.
157.
BrowningRAWadeDRMarcinczykMLongGLJobePC. Regional brain abnormalities in norepinephrine uptake and dopamine beta-hydroxylase activity in the genetically epilepsy- prone rat. J Pharmacol Exp Ther1989;249:229–235.
158.
DaileyJWJobePC. Indices of noradrenergic function in the central nervous system of seizure-naive genetically epilepsy-prone rats. Epilepsia1986;27(6): 665–670.
159.
FaingoldCL. The genetically epilepsy-prone rat. Gen Pharmacol1988;19:331–338.
160.
JobePCLairdHEKoKHRayTDaileyJW. Abnormalities in monoamine levels in the central nervous system of the genetically epilepsy-prone rat. Epilepsia1982;23(4): 359–366.
161.
MishraPKDaileyJWReigelCEJobePC. Brain norepinephrine and convulsions in the genetically epilepsy- prone rat: Sex-dependent responses to Ro 4–1284 treatment. Life Sci1988;42:1131–1137.
162.
NicolettiFBarbacciaMLLadarolaMJPozziOLairdHE. Abnormality of alpha 1-adrenergic receptors in the frontal cortex of epileptic rats. J Neurochem1986;46:270–273.
163.
DaileyJWReigelCEMishraPKJobePC. Neurobiology of seizure predisposition in the genetically epilepsy-prone rat. Epilepsy Res1989;3:3–17.
164.
DaileyJWMishraPKKoKHPennyJEJobePC. Noradrenergic abnormalities in the central nervous system of seizure-naive genetically epilepsy-prone rats. Epilepsia1991;32:168–173.
165.
DaileyJWMishraPKKoKHPennyJEJobePC. Serotonergic abnormalities in the central nervous system of seizure-naive genetically epilepsy-prone rats. Life Sci1992;50:319–326.
166.
JobePCKoKHDaileyJW. Abnormalities in norepinephrine turnover rate in the central nervous system of the genetically epilepsy-prone rat. Brain Res1984;290:357–360.
167.
JobePCRayTB. Effects of norepinephrine and 5-hydroxytryptamine reuptake inhibitors on electrically-induced spinal cord seizures in rats. Res Commun Chem Pathol Pharmacol1980;30:185–188.
168.
JobePCRayTB. The effects of reserpine, iproniazid and L-dopa on electrically- induced spinal cord seizures. Res Commun Chem Pathol Pharmacol1980;29:417–427.
169.
YanQSMishraPKBurgerRLBettendorfAFJobePCDaileyJW. Evidence that carbamazepine and antiepilepsirine may produce a component of their anticonvulsant effects by activating serotonergic neurons in genetically epilepsy-prone rats. J Pharmacol Exp Ther1992;261:652–659.
170.
StullREJobePCGeigerPFFergusonGG. Letter: Effects of dopamine receptor stimulation and blockade on Ro 4-1284-induced enhancement of electroshock seizure. J Pharm Pharmacol1973;25:842–844.
171.
JobePCPicchioniALChinL. Enhancement of audiogenic seizure by modification of brain amine metabolism. Fed Proc1969;28:795. Abstract.
172.
SchlesingerKBogganWOFreedmanDX. Genetics of audiogenic seizures: I. Relation to brain serotonin and norepinephrine in mice. Life Sci1965;4: 2345–2351.
173.
KelloggC.Serotonin metabolism in the brains of mice sensitive or resistant to audiogenic seizures. J Neurobiol1971;2:209–219.
174.
LehmannA.Audiogenic seizures data in mice supporting new theories of biogenic amines mechanisms in the central nervous system. Life Sci1967;6:1423–1431.
175.
ShaywitzBAYagerRDGordonJW. Ontogeny of brain catecholamine turnover and susceptibility to audiogenic seizures in DBA/2J mice. Dev Psychobiol1978;11:243–250.
176.
LairdHEDaileyJWJobePC. Neurotransmitter abnormalities in genetically epileptic rodents. Fed Proc1984;43:2505–2509.
177.
BrowningRAClarkKBNaritokuDKSmithDCJensenRA. Loss of anticonvulsant effect of vagus nerve stimulation in the pentylenetetrazol seizure model following treatment with 6-hydroxydopamine or 5,7-dihydroxytryptamine. Society for Neuroscience1997;23:2424. Abstract.
178.
KrahlSEClarkKBSmithDCBrowningRA. Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. Epilepsia1998;39(7): 709–714.
179.
NaritokuDKTerryWJHelfertRH. Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve. Epilepsy Res1995;22:53–62.
180.
JobePCDeoskarVUBurgerRLDaileyJWKoKHMishraPK. Norepinephrine and serontonin release during seizures in GEPRs and non-epileptic rats: Analysis of one minute microdialysis samples. Society for Neuroscience Abstracts1995;21(3): 1966. Abstract.
181.
JobePCKoKHMishraPK. Norepinephrine release during seizures in GEPR and non-epileptic rats: Analysis of one minute microdialysis samples. Epilepsia1995;36(4): 18. Abstract.
182.
KokaiaMKalenPBengzonJLindvallO.Noradrenaline and 5-hydroxytryptamine release in the hippocampus during seizures induced by hippocampal kindling stimulation: An in vivo microdialysis study. Neuroscience1989;32(3): 647–656.
183.
IshiharaKSasaM.Mechanism underlying the therapeutic effects of electroconvulsive therapy (ECT) on depression. Jpn J Pharmacol1999;80(3): 185–189.
184.
MacDonaldRL. Is there a mechanistic basis for rational polypharmacy?Epilepsy Res1996;11(suppl): 79–93.
185.
CavalheiroEAFilhoCalderazzo LSBortolottoZAMelloLTurskiL.Anticonvulsant role of adenosine. Pol J Pharmacol Pharm1987;39:537–543.
186.
FaingoldCLBrowningRA. Mechanisms of anticonvulsant drug action. I. Drugs primarily used for generalized tonic-clonic and partial epilepsies. Eur J Pediatr1987;146: 2–7.
187.
MeldrumBS. Excitatory amino acid transmitters in epilepsy. Epilepsia1991;32(suppl12): S1–S3.
188.
McLeanMJMacDonaldRL. Multiple actions of phenytoin on mouse spinal cord neurons in cell culture. J Pharmacol Exp Ther1983;227:779–789.
189.
McLeanMJMacDonaldRL. Carbamazepine and 10,11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther1986;238:727–738.
190.
MacDonaldRLBarkerJL. Enhancement of GABA-mediated postsynaptic inhibition in cultured mammalian spinal cord neurons: A common mode of anticonvulsant action. Brain Res1979;167:323–336.
191.
TwymanRERogersCJMacDonaldRL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol1989;25:213–220.
192.
DaileyJWReithMEAYanQSLiMYJobePC. Anticonvulsant doses of carbamazepine increase hippocampal extracellular serotonin in genetically epilepsy-prone rats: Dose response relationships. Neurosci Lett1997;227(1): 13–16.
193.
DaileyJWReithMESteidleyKRMilbrandtJCJobePC. Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia1998;39(10): 1054–1063.
194.
DaileyJWReithMEYanQSLiMYJobePC. Carbamazepine increases extracellular serotonin concentration: Lack of antagonism by tetrodotoxin or zero Ca2+. Eur J Pharmacol1997;328(2–3): 153–162.
195.
SouthamEKirkbyDHigginsGAHaganRM. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol1998;358(1): 19–24.
196.
BiggsCSPearceBRFowlerLJWhittonPS. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: An in vivo microdialysis study. J Neurochem1992;59:1702–1708.
197.
WhittonPSFowlerLJ. The effect of valproic acid on 5-hydroxytryptamine and 5-hydroxyindoleacetic acid concentration in hippocampal dialysates in vivo. Eur J Pharmacol1991;200:167–169.
198.
OkadaMKanekoSHiranoTIshidaMKondoTOtaniK. Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca-2+ dependent dopamine release. Epilepsy Res1992;13:113–119.
199.
OkadaMHiranoTKawataYMurakamiTWadaKMizunoK. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res1999;34(2–3): 187–197.
200.
KanekoSOkadaMHiranoTKondoTOtaniKFukushimaY.Carbamazepine and zonisamide increase extracellular dopamine and serotonin levels in vivo, and carbamazepine does not antagonize adenosine effect in vitro: Mechanisms of blockade of seizure spread. Jpn J Psychiatry Neurol1993;47(2): 371–373.
201.
BarryJJLembkeAHuynhN.Affective disorders in epilepsy. In: EttingerABKannerAM, (eds). Psychiatric Issues in Epilepsy: A Practical Guide to Diagnosis and Treatment. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001: 45–71.
202.
GuerriniRBelmonteAGentonP.Antiepileptic drug-induced worsening of seizures in children. Epilepsia1998;39(suppl3): S2–S10.
203.
KochenSGiaganteBOddoS.Spike-and-wave complexes and seizure exacerbation caused by carbamazepine. Eur J Neurol2002;9(1): 41–47.
204.
Adverse reactions to antiepileptic drugs: A follow-up study of 355 patients with chronic antiepileptic drug treatment. Collaborative Group for Epidemiology of Epilepsy. Epilepsia1988;29(6): 787–793.
205.
BauerJ.Seizure-inducing effects of antiepileptic drugs: A review. Acta Neurol Scand1996;94(6): 367–377.
206.
SneadOCHoseyLC. Exacerbation of seizures in children by carbamazepine. N Engl J Med1985;313:916–921.
207.
BuckleyNADawsonAHWhyteIMHenryDA. Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet1994;343:159–162.
208.
AlldredgeBK. Seizure risk associated with psychotropic drugs: Clinical and pharmacokinetic considerations. Neurology1999;53(suppl2): S68–S75.
209.
CurranSde PauwK.Selecting an antidepressant for use in a patient with epileps: Safety considerations. Drug Safety1998;18(2): 125–133.
210.
PisaniFSpinaEOteriG.Antidepressant drugs and seizure susceptibility: From in vitro data to clinical practice. Epilepsia1999;40(suppl10): S48–S56.
211.
PisaniFOteriGCostaCDi RaimondoGDi PerriR. Effects of psychotropic drugs on seizure threshold. Drug Safety2002;25(2): 91–110.
212.
TrimbleMR. Antidepressant drugs and convulsions. Lancet1980;1:307.
213.
TrimbleMR. New antidepressant drugs and the seizure threshold. Neuropharmacology1980;19:1227–1228.
214.
WongICLhatooSD. Adverse reactions to new anticonvulsant drugs. Drug Safety2000;23(1): 35–56.
215.
SpillerHA. Management of carbamazepine overdose. Pediatr Emerg Care2001;17(6): 452–456.
216.
SpillerHACarlisleRD. Status epilepticus after massive carbamazepine overdose. J Toxicol Clin Toxicol2002;40(1): 81–90.
217.
OsorioIPeltzerJReedR.Carbamazepine and phenytoin exacerbate primary generalized epilepsy. Epilepsia1996;37(suppl5): 93. Abstract.
218.
OsorioIBurnstineTHRemlerBManon-EspaillatRReedRC. Phenytoin-induced seizures: A paradoxical effect at toxic concentrations in epileptic patients. Epilepsia1989;30(2): 230–234.
219.
BournWMGarrettRLReigelCERisingerFO. Reduction of flurazepam convulsive threshold by Ro 15–1788. Psychopharmacology1985;85:267–270.
220.
SpillerHARamoskaEAKrenzelokEPSheenSRBorysDJVillalobosD. Bupropion overdose: A 3-year multi-center retrospective analysis. Am J Emerg Med1994;12:43–45.
221.
GarrettRLBournWM. Convulsant component of a depressant benzodiazepine. Life Sci1985; 37; 1933–1939.
